NOVC.DE - NOVO-NORDISK NAM.B DK-,20
| Previous Close | 52.00 |
| Open | 52.12 |
| Bid | 52.31 x N/A |
| Ask | 52.49 x N/A |
| Day's Range | 52.00 - 52.51 |
| 52 Week Range | 38.12 - 52.51 |
| Volume | 26,041 |
| Avg. Volume | 15,802 |
| Market Cap | N/A |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Reuters VideosWhy this diabetes patient fears a no-deal Brexit
Her daily routine is a matter of life and death for Georgina. She is one of Britain's one million diabetics now facing the possibility of medical shortages if the UK plunges out of the European Union without a deal at the end of October. (SOUNDBITE) (English) LONDON RESIDENT AND DIABETES PATIENT, GEORGINA, SAYING: "I can't tell you how worried I am about that. It's life-threatening for me." Her fears have been exacerbated by the British government's own planning for a worst case scenario. The Yellowhammer document suggests the important Calais to Dover trade route could face months of disruption, and the pharmaceuticals industry is particularly vulnerable. That's because three quarters of the 37 million packs of drugs imported from Europe each month, come through the short straits route. Georgina is concerned that the medical supplies she depends on could dwindle. She tests her blood sugar levels four times a day to work out how much of an insulin boost she needs at meal times, in addition to a pump that gives her a low level dosage of insulin 24 hours a day. (SOUNDBITE) (English) LONDON RESIDENT AND DIABETES PATIENT, GEORGINA, SAYING: "I can live without the pump and I can live without all the bits and pieces that go with the pump but I cannot live without the blood testing strips because that's just as important, nearly as important, as having an adequate insulin supply. And the two really go so hand in hand, that's the one thing I don't think people realize." She may take some comfort from private sector preparations. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "At Novo Nordisk we've been preparing for the last three years, if not more than that, for the worst-case scenario." Pinder Sahota is the UK general manager of the world's biggest insulin maker, Novo Nordisk. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "So what we've done is we've increased our stock level from - a normal average of stock-holding is six weeks, we've increased that to 18 weeks." That's a warehouse capacity of 3.8 million packs of insulin. Piled up - they'd stand 12 times the height of London's Shard skyscraper. Novo Nordisk has also reserved spaces on alternate ferry routes and air freight if required while exploring other factors such as what to do in the event of fuel shortages. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "Whilst we can control what we can control, it's the uncertainties of how long will the delays be, that are factors outside our control. But we're doing everything we can to ensure that the patients can continue to get the medicines that they need." But the situation is increasing tensions between industry and the government - and not just around the intricacies of planning for a no-deal. Hugo Fry, UK managing director of France's Sanofi, also says that patients have to be prioritized. (SOUNDBITE) (English) MANAGING DIRECTOR OF SANOFI UK, HUGO FRY, SAYING: "Of course, we're starting to ask ourselves the question... although we're happy to do it, it is starting to weigh on our balance sheet, on our logistics, keeping all this additional stock in the country." And that leads to another frustration - that while the companies like Sanofi and Novo Nordisk dedicate huge resources to such preparation, they are having to spend less time on their normal job - bringing innovative drugs to market.
- Reuters
UPDATE 2-Novo Nordisk nudges up 2019 sales outlook as new drugs excel
Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs. Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. The world's largest maker of diabetes drugs is betting on new treatments, including a first-of-its-kind tablet, to offset pricing pressure from competing insulins and U.S. lawmakers, who have been critical of rising drug costs.
- Reuters
Novo Nordisk nudges up 2019 sales outlook as new drugs excel
Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs. Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. The world's largest maker of diabetes drugs is betting on new treatments, including a first-of-its-kind tablet, to offset pricing pressure from competing insulins and U.S. lawmakers, who have been critical of rising drug costs.
- Simply Wall St.
Can Novo Nordisk A/S's (CPH:NOVO B) ROE Continue To Surpass The Industry Average?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- Simply Wall St.
An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 25% Undervalued
Does the October share price for Novo Nordisk A/S (CPH:NOVO B) reflect what it's really worth? Today, we will estimate...
- Benzinga
Cool Chain Association Calls For Data Sharing
Cool chain partners are changing their mindsets to join shippers and start-ups shaping the supply chain of the future, according to speakers at the recent Cool Chain Association's (CCA) pharma and biosciences conference in Paris. Conference delegates also heard that the air cargo industry could make a difference in final mile delivery that could save the lives of infants. The CCA, which hosts two regular events each year, one on pharma and one on perishables, brings together industry leaders from across the cool chain to network.
- Investor's Business Daily
How Novo Nordisk Is Aiming To Take A Slice Of Lilly's Diabetes Market
Novo Nordisk's newest diabetes treatment, an oral drug called Rybelsus, won't immediately gouge another medicine from pharmaceutical company Eli Lilly. Both are GLP-1 receptor agonists.
- Reuters
Novo Nordisk targets bigger slice of diabetes market with new tablet
Danish drugmaker Novo Nordisk is aiming for a big slice of the multibillion-dollar diabetes market with a new pill, approved by U.S. authorities on Friday, that caters for patients with an aversion to needles. The company built its position as the world's biggest insulin maker on the back of injectable drugs, but now aims to transform the market with a first-of-its-kind tablet version of its semaglutide drug. While more than 70% of diabetes prescriptions in the United States are already for oral treatments, none of these are from the GLP-1 class that Novo specialises in, and which are viewed as highly effective medicines that stimulate insulin production.
ReutersUPDATE 2-Novo Nordisk wins U.S. approval for first-of-its-kind oral diabetes drug
The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker which hopes to transform the market by offering patients a non-injectable treatment. The world's biggest producer of diabetes drugs already sells an injectable once-weekly version of semaglutide under the brand name Ozempic at nearly $800 per month. Novo did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be "competitively priced" with other drugs in the same "GLP-1" class of medicines.
- Investor's Business Daily
How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal
Novo Nordisk stock popped Tuesday after an analyst suggested the pharmaceutical company's oral diabetes treatment, semaglutide, could swipe share from Eli Lilly's rival drug, Trulicity.
- Reuters
Factbox: Britain's insulin providers prepare for Brexit fallout
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.
- Reuters
With a backup to the backup, insulin makers say they're primed for Brexit
For two men trained as scientists, the bosses of Britain's major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit. With Britain set to leave the European Union within weeks, Pinder Sahota at the world's biggest insulin maker Novo Nordisk, and Sanofi's Hugo Fry have rebuilt operations to withstand the most turbulent of events.
- Benzinga
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
Biotech stocks rebounded in last week after declining modestly in the previous week. Some of the drugs that cleared the FDA hurdle this week include Ardelyx Inc (NASDAQ: ARDX )'s constipation drug Ibsrela; ...
- Reuters
UPDATE 1-Novo Nordisk to cut insulin prices in the U.S.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
- Reuters
Novo Nordisk to cut insulin prices in the U.S.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
- Motley Fool
2 Stocks to Watch in September
These two businesses could receive a big boost this month if certain events fall in their favor.
- Reuters
UPDATE 2-Novo Nordisk contests Danish lawsuit claiming $1.75 bln
Danish insulin-maker Novo Nordisk said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement. "Novo Nordisk disagrees with the allegations and is prepared to defend the company in this matter," the company said. The securities lawsuit was filed by a number of shareholders who claims compensation worth a total of 11.785 billion Danish crowns ($1.75 billion) based on trading of Novo shares for two years from February 2015.
